Pet Allergy Treatment Market Size - By Drug Class, By Pet Type, By Route of Administration, By Distribution Channel - Global Forecast, 2025 - 2034

Pet Allergy Treatment Market Size

The pet allergy treatment market was valued at USD 2.2 billion in 2024 and is estimated to reach USD 4 billion by 2034, growing at a CAGR of 6.3% from 2025 to 2034. The market is witnessing rapid growth owing to the rising incidence of allergies noted in pets. According to Banfield Pet Hospital data, flea allergy prevalence was about 1.8% in dogs and 2% in cats, while environmental allergies affected 3.6% of dogs and 0.4% of cats, with both on an increasing trend over the past decade.

As the number of companion animals rises globally, a large volume of pet population, including both dogs and cats, have been diagnosed with allergic conditions such as flea allergies, food allergens, and other environmental allergens. This growing prevalence of allergic conditions in pets increases the demand for effective treatments to manage these conditions, thereby fostering market growth.
 

As owners increasingly consider pets as a part of their family, the average amount spent per household on pets is rising. For example, an average American pet owner spent USD 1,960 on their pet(s) in 2023. The average pet dog costs USD 143 per month in 2024 and cat ownership costs USD 90.50 per month. Therefore, as households increase their spending on pets, there is a higher spending on pet healthcare, which consequently drives the demand for various pharmaceutical products, including pet allergy medications.
 

The pet allergy treatments is engaged in managing and control the allergic conditions of pets. These treatments are intended for different forms of allergic conditions including skin allergies, flea allergies, environmental allergies (dust mites, pollen), and food allergies. Treatment include the use of antihistamines, corticosteroids, topical medications, and allergy specific immunotherapy drugs.
 

Pet Allergy Treatment Market Trends

• As per GlobalPET, there are over one billion animals kept as pets worldwide. The number of households with pets in the U.S., Brazil, Europe, and China alone has exceeded half a billion. Also, more than half of the world's families are said to have at least one pet.  Such a high volume of pets increases the demand for various pet care products, thus boosting the market growth.
   
• Rapid rise in allergic conditions in pets in recent years has significantly aided in the market growth. Different types of allergies in pet animals have become increasingly common, leading to a surge in demand for treatment.
   
• In the U.S., allergies in dogs and cats have been rising notably over the past decade. For dogs, environmental allergies have increased by about 30% in the last 10 years, with allergic skin disease being the most common issue observed by veterinarians. Flea allergies have also increased, with a 12.5% rise in dogs and a 67.3% rise in cats over the same period.
   
• With rise in awareness among pet owners about the effect of these allergies on pet's overall health and life increases, the pet parents are seeking effective therapeutics to manage these allergic conditions.
   
• Many veterinarians and pet owners are adopting medications such as antihistamines, immunotherapy, and other drugs to manage allergies in pets, thus fueling the market growth.
   
• Moreover, growing awareness among pet owners regarding preventive care has enhanced the acceptance of these products, which are highly crucial for the growth of this market.
   
• Rapidly growing veterinary infrastructure in emerging economies, availability of advanced drugs to manage allergies, and rising adoption of pet insurance are some other factors that are driving the market growth.
   

Trump Administration Tariffs

• The tariffs imposed by the Trump administration, especially those placed on Chinese goods, affected the market of pet allergy treatments by changing the global supply chains and increasing the import value of raw materials and finished goods.
   
• With increased tariffs on these products, wholesalers and distributors may face an increased cost in production and procurement.
   
• The volatility of trade policies during this period may create supply chain disruptions which, in turn, led to unavailability or delayed access to certain allergy medications.
   
• Collectively, the Trump-era tariffs convolutely impacted the market for pet allergy treatments by increasing costs of basic resources, fragmenting supply chains, and adding uncertainty, all of which impacted the manufacturers and consumers.
   

Pet Allergy Treatment Market Analysis

Learn more about the key segments shaping this market

Download Free PDF

In 2024, the global market for pet allergy treatment was valued at USD 2.23 billion.  Based on the drug class, the market is segmented into antihistamines, corticosteroids, immunotherapy, and other drug classes. The antihistamines segment accounted for the highest market share and was valued at USD 908 million in 2024.
 

• The widespread usage of antihistamines as a first-line treatment for allergic reactions in companion animals is a key factor contributing to its high market share in the pet allergy treatment market.
   
• Veterinarians commonly prescribe antihistamines, as these drugs provide prompt relief from allergic signs like pruritus, sneezing, and inflammation. These drugs are known to provide rapid action and are relatively safe.
   
• Also, antihistamines are easy to administer to different species and sizes of animals as they can be dispensed in several forms such as tablets and liquids, and even injectable forms.
   
• Moreover, the management of mild to moderate allergic reactions with these medications, combined with their availability without a prescription, enhances the usage and sales of these products.

Learn more about the key segments shaping this market

Download Free PDF

Based on the pet type, the global pet allergy treatment market is categorized into dogs, cats, rabbits, and pet types. The dogs segment dominated the market with 48.2% market share in 2024.
 

• The increasing segmental growth is attributed to the rising adoption rate of dogs as companion animals, coupled with growing expenditure on dogs. For instance, in 2021, according to the American Pet Products Association (APPA), 90.5 million families own a pet in the U.S. among which 69 million (over 76%) households own a dog.
   
• Also, countries in Europe such as U.K. Poland, France are noted to have some of the highest population of pet dogs. Thus, the higher adoption rates along with increased spending is expected to propel the segmental growth.
   
• The incidence of allergic conditions such as atopic dermatitis in the dog population is on the rise and is expected to accelerate growth in the market. According to data published in the Journal of Veterinary Medicine in February 2024, atopic dermatitis, a chronic allergic skin condition, is prevalent in dogs, impacting 20-30% of the canine population.
   
• Further, growing disposable income in developing economies and launch of advanced dog specific products will further spur segmental growth during the forecast timeframe.
   

Based on the route of administration, the market is categorized into oral, parenteral, and topical. The oral segment dominated the market and is anticipated to reach 2.2 billion by 2034.
 

• The oral segment holds a high market share in the pet allergy treatment market due to the ease of administration of these drugs. Oral dosage forms such as tablets, chews, and liquids are preferred by pet owners as it is less invasive than other forms such as injections and is easier to use in a pet's routine. This method of treatment increases compliance, especially for long-term allergy treatment and facilitates consistent treatment.
   
• Also, oral dosage forms can be easily incorporated in food, which increases the adoption rate of these products. The wide range of oral medications tailored to specific conditions of pet allergies, like atopic dermatitis and food allergies, is continuously expanding.
   
• Pharmaceutical companies are producing more taste-appealing drugs which is further supporting its adoption.
   

Based on the distribution channel, the market is classified into veterinary hospital pharmacies, retail pharmacies, and online pharmacies. In 2024, the veterinary hospital pharmacies segment held highest market share and is expected to showcase growth rate of over 6.4% till 2034.
 

• Veterinary hospital pharmacies hold a significant market share in the pet allergy treatment market due to their direct access to veterinary professionals and the ability to provide specialized medications tailored to individual pet needs.
   
• These pharmacies are typically equipped with trained professionals who can provide specialized guidance on allergy treatments.
   
• Additionally, they offer a range of allergy treatments which are prescribed based on thorough assessments by veterinarians. Their ability to provide customized care, combined with the assigned pet owners place in veterinary hospitals, drives the growth of this segment.

Looking for region specific data?

Download Free PDF

North America pet allergy treatment market held the largest market share of 41.9% in 2024 and is anticipated to expand at a 5.9% CAGR till 2034. The U.S. market is USD 851.2 million in 2024.
 

• High rates of pet ownership in the country coupled with availability of advanced treatment options, drives the market growth. The growing humanization of pets in the U.S. also increases spending on veterinary care.
   
• According to the 2021-2022 National Pet Owners Survey by the American Pet Products Association (APPA), 70% of the U.S. households owned at least one type of pet. Similarly, almost 69 million of the U.S. households have at least one dog, and 45.3 million have at least one cat.
   
• Further, studies report that there has been a 30% increase in allergy cases in dogs over the past 10 years. Thus, such a high volume of pets in the country coupled with high incidence of allergies in pets, increases the demand for pet allergy treatments.
   
• Moreover, the U.S. market is strengthened by the presence of major companies in the region, which ensure a constant supply of advanced and effective therapies for pets.
   

Europe pet allergy treatment market is anticipated to witness significant growth in the coming years. UK market is anticipated to witness considerable growth over the analysis period.
 

• UK holds a substantial share in the European market due to strong culture of pet ownership, advanced veterinary services, and high concern for health issues related to animals.
   
• As per the PDSA Animal Wellbeing Report 2024, 51% of UK adults own a pet, of which, 28% of UK adults have a dog, an estimated population of 10.6 million pet dogs, and 24% of adults have a cat, an estimated population of 10.8 million pet cats.
   
• This large number of companion animals such as dogs and cats create an increasing demand for various pharmaceutical products, including pet allergy treatment medications.
   
• The market growth is also supported by government initiatives and regulations related to pet care, as well as strict animal health policies.
   

The Asia Pacific pet allergy treatment market held a market share of 20.5% in 2024. Indian market is predicted to grow significantly over the forecast period.
 

• The market growth is attributed to the rising incidence of allergic conditions in pets, growing expenditure on pets owing to high disposal income, and increasing access to advanced veterinary infrastructure in the region.
   
• India has a large pet population with over 31 million pet dogs and 2.44 million pet cats. The increasing pet ownership and rising disposable income in the country coupled with high expenditure on pet care will offer lucrative market growth opportunity in the country.
   
• Also, rapidly expanding veterinary infrastructure in the country such as veterinary hospitals, clinics, as well as distribution channels including retails stores and online platforms, will further enhance market growth.
   

Brazil pet allergy treatment market is anticipated to witness significant growth in the Latin America.
 

• Brazil has the third-largest pet population in the world with 160 million pets, of which 60 million are dogs, 30 million cats, and 32 million pet-owning households. Such high volume of pets coupled with strong growth in veterinary expenditure is anticipated to foster market growth.
   
• Also, the presence of several international as well as local pet care companies in the country aid in market growth.
   
• Furthermore, the country’s improving veterinary infrastructure is expected to support market growth, with pet allergy treatments becoming more accessible and sought after across urban and rural areas alike.
   

Pet Allergy Treatment Market Share

The pet allergy treatment industry is highly competitive, with several key companies striving to develop novel formulations in the market. Several major organizations, local small players, and start-ups are joining the industry competition. Top 6 companies in the pet allergy treatment industry such as Zoetis, Elanco Animal Health, Merck Animal Health, Virbac, Vetoquinol, and Boehringer Ingelheim International account for approximately 55 - 60% of the global market share. The major market players implement several strategies to maintain a competitive edge in the market. These players are engaged in strategic acquisitions, mergers, collaborations, partnerships, expansions, and product launches among other strategies.
 

Additionally, there are several local and regional players operating in the market who are boosting competition by providing affordable options at lower costs. These players are also involved in several strategies such as mergers, acquisitions, and novel product launches to expand their product offerings.
 

Pet Allergy Treatment Market Companies

Few of the prominent players operating in the pet allergy treatment industry include:

• Boehringer Ingelheim International
• Ceva Santé Animale
• Dechra
• Elanco
• Idexx
• Merck Animal Health
• Neogen Corporation
• PetIQ
• Provetica
• Vetoquinol
• Virbac
• Zoetis
   
• Zoetis is a key player in animal health, renowned for its extensive portfolio of pet allergy treatments. Notable products include Apoquel and Cytopoint, which are widely used for managing allergic dermatitis in dogs. These products are widely trusted by veterinarians for managing itch and inflammation caused by allergies. The company’s strong R&D pipeline and global distribution network help maintain its dominant position.
   
• Boehringer Ingelheim offers a range of allergy treatment products, such as Atopica and Vetadryl, catering to various allergic conditions in pets. It leverages deep scientific expertise to deliver immunomodulatory and antihistamine solutions for pets. The company also invests heavily in innovation to support long-term therapeutic development in veterinary dermatology.
   
• Elanco provides a variety of allergy treatments, including Comfortis and Trifexis, addressing flea allergies and other allergic conditions in pets. The company focuses on companion animal well-being through a combination of parasiticides and anti-allergy solutions. Elanco’s acquisition strategies and product diversification contribute to its growing presence in the allergy segment.
   

Pet Allergy Treatment Industry News

• In September 2024, Boehringer Ingelheim acquired Saiba Animal Health AG, a company dedicated to developing innovative therapeutic medicines for chronic diseases in pets. Saiba Animal Health’s innovative technology platform uses a first-of-its-kind therapeutic vaccine approach, which is designed to create an immune response, targeting chronic diseases such as allergy, inflammation and pain. This acquisition helped the company to enhance its capabilities in the pet therapeutics sector.
   
• In September 2024, Elanco Animal Health announced FDA approval and launch of Zenrelia (ilunocitinib tablets), a new oral medication for dogs designed to manage allergic dermatitis and atopic dermatitis. This approval marks a significant advancement in canine dermatology, providing an effective treatment option for pruritus (itching) associated with these conditions in dogs aged one year and older.
   
• In June 2023, Zoetis Inc. received FDA approval for Apoquel Chewable, a chewable form of oclacitinib designed for the management of pruritus associated with allergic dermatitis and atopic dermatitis in dogs aged twelve months and older. This new formulation represents a significant advancement in veterinary dermatology, as it is the first chewable treatment available in the U.S. for these conditions, which affect a substantial portion of the canine population.
   

The pet allergy treatment market research report includes in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 - 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Drug Class

• Antihistamines
• Corticosteroids
• Immunotherapy
• Other drug classes

Market, By Pet Type

• Dogs
• Cats
• Rabbits
• Other pet types

Market, By Route of Administration

• Oral
• Parenteral
• Topical

Market, By Distribution Channel

• Veterinary hospital pharmacies
• Retail pharmacies
• Online pharmacies

The above information is provided for the following regions and countries:

• North America
  • U.S.
  • Canada
• Europe
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea 
• Latin America
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa
  • Saudi Arabia
  • South Africa
  • UAE